Recent Updates
Recently added Catalysts
BMRN Positive Sentiment

BioMarin to Participate in Upcoming Investor Conferences

Key Takeaway: BioMarin Pharmaceutical Inc. will present at several investor conferences in September 2026, including the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. The company is recognized for its innovative approach to drug development and has a strong pipeline of therapies for genetically defined conditions. Live audio webcasts of the presentations will be available.
Price reaction · baseline $64.84 (2026-09-01 close) · hit pre-market · clean, no other BMRN news in the window
day 0 close · peak
+3.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • BioMarin is participating in multiple investor conferences.
  • The company has a strong clinical and preclinical pipeline.
  • BioMarin has a proven track record of innovation.
  • They focus on delivering medicines for rare genetic conditions.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+20%
120-day peak, hindsight
Typical move
8.8%
average across 7 past catalysts
Lead asset
Valoctocogene roxaparvovec
Phase 3 · Hemophilia A

Full Press Release Details

• Wells Fargo 21st Annual Healthcare Conference, September 9 at 3:00 pm EST
• Cantor Global Healthcare Conference 2026, September 10 at 10:20 am EST
• Citi 's 2026 Biopharma Back to School Conference, September 10 at 1:00 pm EST
• Morgan Stanley 24th Annual Global Healthcare Conference, September 14 at 10:00 am EST
SAN RAFAEL, Calif. , Sept. 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in September.
An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/ . An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients.
To learn more, please visit www.biomarin.com .
Contacts:
Investors
Media
Traci McCarty
Marni Kottle
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.

Frequently Asked Questions

When is the Wells Fargo Healthcare Conference?

The Wells Fargo 21st Annual Healthcare Conference is on September 9 at 3:00 pm EST.

What is BioMarin's focus?

BioMarin focuses on delivering medicines for genetically defined rare diseases.

Where can I access the conference webcasts?

The webcasts will be available live on BioMarin's investor website.

How many therapies does BioMarin have?

BioMarin has nine commercial therapies and a robust pipeline.

Last updated: Sep 2, 2026